Idiosyncratic Adverse Reactions to Antiepileptic Drugs

Summary:  Idiosyncratic drug reactions may be defined as adverse effects that cannot be explained by the known mechanisms of action of the offending agent, do not occur at any dose in most patients, and develop mostly unpredictably in susceptible individuals only. These reactions are generally thought to account for up to 10% of all adverse drug reactions, but their frequency may be higher depending on the definition adopted. Idiosyncratic reactions are a major source of concern because they encompass most life‐threatening effects of antiepileptic drugs (AEDs), as well as many other reactions requiring discontinuation of treatment. Based on the underlying mechanisms, idiosyncratic reactions can be differentiated into (1) immune‐mediated hypersensitivity reactions, which may range from benign skin rashes to serious conditions such as drug‐related rash with eosinophilia and systemic symptoms; (2) reactions involving unusual nonimmune‐mediated individual susceptibility, often related to abnormal production or defective detoxification of reactive cytotoxic metabolites (as in valproate‐induced liver toxicity); and (3) off‐target pharmacology, whereby a drug interacts directly with a system other than that for which it is intended, an example being some types of AED‐induced dyskinesias. Although no AED is free from the potential of inducing idiosyncratic reactions, the magnitude of risk and the most common manifestations vary from one drug to another, a consideration that impacts on treatment choices. Serious consequences of idiosyncratic reactions can be minimized by knowledge of risk factors, avoidance of specific AEDs in subpopulations at risk, cautious dose titration, and careful monitoring of clinical response.

[1]  Sean Hennessy,et al.  Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. , 2003, The New England journal of medicine.

[2]  T. Vulliamy,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 2000, Bailliere's best practice & research. Clinical haematology.

[3]  V. Drory,et al.  Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. , 1993, Clinical neuropharmacology.

[4]  K. Landsteiner,et al.  STUDIES ON THE SENSITIZATION OF ANIMALS WITH SIMPLE CHEMICAL COMPOUNDS , 1935, The Journal of experimental medicine.

[5]  P. Berloco,et al.  Acute Hepatitis Associated with Lamotrigine and Managed with the Molecular Adsorbents Recirculating System (MARS) , 2005, Epilepsia.

[6]  A. Sagone,et al.  Metabolism of phenytoin and covalent binding of reactive intermediates in activated human neutrophils. , 1995, Biochemical pharmacology.

[7]  Hitoshi Yamaguchi,et al.  Pure red cell aplasia during carbamazepine monotherapy , 1997, Brain and Development.

[8]  M. Okada,et al.  Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus , 1997, Epilepsy Research.

[9]  R. Schlienger,et al.  Antiepileptic Drug Hypersensitivity Syndrome , 1998, Epilepsia.

[10]  L. Feldman-Winter,et al.  Acute pancreatitis in children from Valproic acid: case series and review. , 2003, Pediatric neurology.

[11]  R. Tigelaar,et al.  Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. , 1999, Journal of the American Academy of Dermatology.

[12]  R. Stern,et al.  The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. , 1990 .

[13]  M. Brodie,et al.  Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy , 1999, Epilepsy Research.

[14]  I. Rosén,et al.  Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam , 2004, Acta neurologica Scandinavica.

[15]  H. Schultz,et al.  Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. , 1999, Acta oncologica.

[16]  J. Hanlon,et al.  Pharmacological and clinical aspects of antiepileptic drug use in the elderly , 2006, Epilepsy Research.

[17]  J. Nordlund,et al.  Cutaneous T-cell lymphoma sparing resolving dermatomal herpes zoster lesions: an unusual phenomenon and implications for pathophysiology. , 2004, Journal of the American Academy of Dermatology.

[18]  K. Otani,et al.  Associations Between Risk Factors for Valproate Hepatotoxicity and Altered Valproate Metabolism , 1992, Epilepsia.

[19]  F. Dreifuss,et al.  Valproic acid hepatic fatalities , 1987, Neurology.

[20]  B. K. Park,et al.  Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[21]  M. Pirmohamed,et al.  ADVERSE DRUG REACTIONS , 1976, BMJ.

[22]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[23]  J. Craig,et al.  Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. , 2004, American journal of ophthalmology.

[24]  T. Bohan,et al.  l‐Carnitine Supplementation in Childhood Epilepsy: Current Perspectives , 1998, Epilepsia.

[25]  S. Johannessen,et al.  Valproate: past, present, and future. , 2006, CNS drug reviews.

[26]  Ai-Young Lee,et al.  Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions , 2004, European Journal of Clinical Pharmacology.

[27]  A. Yamauchi,et al.  Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein. , 1997, Blood.

[28]  R. Schlienger,et al.  Lamotrigine-associated anticonvulsant hypersensitivity syndrome , 1998, Neurology.

[29]  S. Arroyo,et al.  Life-threatening adverse events of antiepileptic drugs , 2001, Epilepsy Research.

[30]  R. Meyboom,et al.  Risk of Aplastic Anemia in Patients Using Antiepileptic Drugs , 2006, Epilepsia.

[31]  I. Choi,et al.  Mechanism for acute oral desensitization to antibiotics , 2006, Allergy.

[32]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[33]  N. Kaplowitz,et al.  Drug-induced liver injury. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  C. D. Thompson,et al.  Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. , 1996, Chemical research in toxicology.

[35]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[36]  N. Kitteringham,et al.  Drug disposition and drug hypersensitivity. , 1987, Biochemical pharmacology.

[37]  P. Greenberger 8. Drug allergy. , 2006, The Journal of allergy and clinical immunology.

[38]  H. Askmark,et al.  Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system , 1990, Acta neurologica Scandinavica.

[39]  G. Krauss,et al.  Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: Potential implications for patients with acute porphyria , 1997, Neurology.

[40]  Stefan Schlesinger,et al.  Possible drug-induced thrombocytopenia secondary to tiagabine , 1999, Neurology.

[41]  P. Hutchinson,et al.  Toxic epidermal necrolysis: current evidence, practical management and future directions , 2005, The British journal of dermatology.

[42]  P. Camfield,et al.  Asymptomatic children with epilepsy , 1986, Neurology.

[43]  J. Cramer,et al.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. , 1985, The New England journal of medicine.

[44]  J. Hanlon,et al.  Pharmacological and clinical aspects of antiepileptic drug use in the elderly , 2006, Epilepsy Research.

[45]  L. Hirsch,et al.  Predictors of Lamotrigine‐associated Rash , 2006, Epilepsia.

[46]  T. Glauser Idiosyncratic Reactions: New Methods of Identifying High‐risk Patients , 2000, Epilepsia.

[47]  P. Demoly,et al.  Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations , 2003, Allergy.

[48]  M. Spitzer,et al.  [Successful hyposensitization treatment of a patient with schizoaffective psychosis and carbamazepine allergy]. , 1993, Der Nervenarzt.

[49]  Reynolds Es,et al.  Liver parenchymal cell injury. IX. Phenobarbital potentiation of endoplasmic reticulum denaturation following carbon tetrachloride. , 1972 .

[50]  M. Blanca,et al.  Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. , 2000, The Journal of allergy and clinical immunology.

[51]  K. Doh,et al.  Clinicopathological and genotypic aspects of anticonvulsant‐induced pseudolymphoma syndrome , 2003, The British journal of dermatology.

[52]  K. Ishak,et al.  Valproate‐Induced Hepatic Injury: Analyses of 23 Fatal Cases , 2007, Hepatology.

[53]  R. Villani,et al.  Shoulder-hand syndrome in neurosurgical patients treated with barbiturates. A long term evaluation. , 2000, Journal of neurosurgical sciences.

[54]  J. George,et al.  Drug‐associated blood dyscrasias , 2001 .

[55]  Dieter Schmidt,et al.  Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs , 2006, Epilepsia.

[56]  L. Ackerman,et al.  Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas , 1959, Cancer.

[57]  H. Masson,et al.  Parkinsonism and/or Cognitive Impairment with Valproic Acid Therapy: A Report of Ten Cases , 2006, Pharmacopsychiatry.

[58]  Rebecca S Gruchalla,et al.  Clinical assessment of drug-induced disease , 2000, The Lancet.

[59]  H. Okubo [Drug-induced hematologic disorders in Japan]. , 1974, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[60]  J. Uetrecht,et al.  New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.

[61]  F. Dreifuss,et al.  Valproic acid hepatic fatalities. , 1989, Neurology.

[62]  G. Zaccara,et al.  Adverse motor effects induced by antiepileptic drugs. , 2004, Epileptic disorders : international epilepsy journal with videotape.

[63]  A. Rettie,et al.  Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. , 1997, The Journal of pharmacology and experimental therapeutics.

[64]  M. Yoshita,et al.  MRI of segmental zoster paresis , 2005, Neurology.

[65]  T. Hanihara,et al.  Carbamazepine-induced hypersensitivity syndrome, associated with human herpesvirus 6 reactivation. , 2004, Journal of clinical psychopharmacology.

[66]  Alasdair Breckenridge,et al.  Meyler's Side Effects of Drugs , 1976 .

[67]  P. Camfield,et al.  Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value. , 1989, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[68]  H. Blain,et al.  Aplastic Anemia Induced by Phenytoin: A Geriatric Case with Severe Folic Acid Deficiency , 2002, Journal of the American Geriatrics Society.

[69]  S. Knowles,et al.  Anticonvulsant Hypersensitivity Syndrome , 1999, Drug safety.

[70]  Munir Pirmohamed,et al.  Fortnightly review: Adverse drug reactions , 1998 .

[71]  M. Harrison,et al.  Phenytoin and dyskinesias: A report of two cases and review of the literature , 1993, Movement disorders : official journal of the Movement Disorder Society.

[72]  F. Dreifuss,et al.  Hepatic Considerations in the Use of Antiepileptic Drugs , 1987, Epilepsia.

[73]  J. Descotes Methods of evaluating immunotoxicity , 2006, Expert opinion on drug metabolism & toxicology.

[74]  P. Fowler Pharmacotherapy: A Pathophysiologic Approach. 3rd Edition , 1997 .

[75]  H. Chan,et al.  Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. , 1997, Journal of the American Academy of Dermatology.

[76]  B. Crickx,et al.  Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. , 2001, Archives of dermatology.

[77]  E. Barnes,et al.  Multisystem adverse reaction to lamotrigine , 1994, The Lancet.

[78]  M. G. O'neil,et al.  Felbamate‐associated fatal acute hepatic necrosis , 1996, Neurology.

[79]  J. Bourgeois,et al.  Valproic acid-induced hyperammonemia: a case report. , 2004, Journal of clinical psychopharmacology.

[80]  S. Knowles,et al.  Idiosyncratic drug reactions: the reactive metabolite syndromes , 2000, The Lancet.

[81]  René H. Levy,et al.  Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII) , 2007, Epilepsy Research.

[82]  J. Roujeau,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.

[83]  E. Perucca,et al.  The Ketogenic diet: from molecular mechanisms to clinical effects , 2006, Epilepsy Research.

[84]  Kazuyoshi Watanabe,et al.  Phenytoin desensitization in a child with symptomatic localization-related epilepsy , 2007, Brain and Development.

[85]  A. Rane,et al.  High incidence of a concentration-dependent skin reaction in children treated with phenytoin. , 1978, British medical journal.

[86]  M. Pirmohamed,et al.  Metabolism of lamotrigine to a reactive arene oxide intermediate. , 2000, Chemical research in toxicology.

[87]  L. Macdougall Pure red cell aplasia associated with sodium valproate therapy. , 1982, JAMA.

[88]  C. Lombroso,et al.  Lamotrigine-induced tourettism , 1999, Neurology.

[89]  N. Gogtay,et al.  Anticonvulsant hypersensitivity syndrome: a review , 2005, Expert opinion on drug safety.

[90]  F. Guengerich,et al.  Cytochrome P450s and other enzymes in drug metabolism and toxicity , 2006, The AAPS Journal.

[91]  E. Perucca,et al.  Adverse effects of antiepileptic drugs , 2005, Acta neurologica Scandinavica. Supplementum.

[92]  Goraya Js,et al.  Carbamazepine-induced immune thrombocytopenia. , 2003 .

[93]  C. DeVane,et al.  Alopecia and mood stabilizer therapy. , 1996, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[94]  A. Bircher,et al.  Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro , 2000, Allergy.

[95]  W. Pichler,et al.  Transfection of Drug-Specific T-Cell Receptors into Hybridoma Cells: Tools to Monitor Drug Interaction with T-Cell Receptors and Evaluate Cross-Reactivity to Related Compounds , 2006, Molecular Pharmacology.

[96]  M. Brodie,et al.  Felbamate: 1997 Update , 1997, Epilepsia.

[97]  R. Stern,et al.  Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study , 1997, Neurology.

[98]  C. Yeh,et al.  Lamotrigine-associated anticonvulsant hypersensitivity syndrome in bipolar disorder , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[99]  M. Britschgi,et al.  Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions , 2002, American journal of clinical dermatology.

[100]  T. Tomson,et al.  Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) , 2004, Epilepsy Research.

[101]  I. Wong,et al.  Psychiatric Adverse Effects of Anticonvulsant Drugs , 1997 .

[102]  K. Lammintausta,et al.  The usefulness of skin tests to prove drug hypersensitivity , 2005, The British journal of dermatology.

[103]  C. Hyson,et al.  Cross Sensitivity of Skin Rashes with Antiepileptic Drugs , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[104]  M. Pirmohamed,et al.  The danger hypothesis--potential role in idiosyncratic drug reactions. , 2002, Toxicology.

[105]  W. Pichler,et al.  Delayed Drug Hypersensitivity Reactions , 2003, Annals of Internal Medicine.

[106]  R. Crausman,et al.  Carbamazepine-induced systemic lupus erythematosus presenting as cardiac tamponade. , 2000, Chest.

[107]  J. Bartra,et al.  Drug neosensitization during anticonvulsant hypersensitivity syndrome. , 2006, Journal of investigational allergology & clinical immunology.

[108]  M. Blaiss,et al.  Drug allergy. , 1988, Pediatric clinics of North America.

[109]  A. Flahault,et al.  Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. , 2002, Journal of the American Academy of Dermatology.

[110]  Parker Wa Letter: Primidone thrombocytopenia. , 1974 .

[111]  J. Roujeau,et al.  Drug rashes. What are the targets of cell-mediated cytotoxicity? , 1994, Archives of dermatology.

[112]  Frederick W. Fraunfelder,et al.  Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. , 2004, Ophthalmology.

[113]  S. Aylett,et al.  Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins , 1999, Postgraduate medical journal.

[114]  L. Calabrese,et al.  Drug‐induced vasculitis , 1996, Current opinion in rheumatology.

[115]  M. Pirmohamed,et al.  Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. , 2003, Molecular pharmacology.

[116]  J. Sackellares,et al.  Safety and Efficacy of Divalproex Sodium Monotherapy in Partial Epilepsy , 1997, Neurology.

[117]  E. Perucca Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age , 2006, Clinical pharmacokinetics.

[118]  W. Santos,et al.  Role of glutathione S-transferases A1-1, M1-1, and P1-1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite. , 2001, Chemical research in toxicology.

[119]  E. Masliah,et al.  CASE REPORT: Fatal Progressive Hepatic Necrosis Associated with Lamotrigine Treatment: A Case Report and Literature Review , 2002, Digestive Diseases and Sciences.

[120]  F. Ferro,et al.  Thrombocytopenia During Valproic Acid Treatment in Young Patients With New-Onset Bipolar Disorder , 2003, Journal of clinical psychopharmacology.

[121]  P. Camfield,et al.  Monitoring for Adverse Effects of Antiepileptic Drugs , 2006, Epilepsia.

[122]  K. Alanko,et al.  Patch testing in cutaneous reactions caused by carbamazepine , 1993, Contact dermatitis.

[123]  M. Schumacher,et al.  A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.

[124]  K. Lammintausta,et al.  Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. , 2005, Acta dermato-venereologica.

[125]  S. Shorvon,et al.  Harnessing the Clinical Potential of Antiepileptic Drug Therapy , 2001, CNS drugs.

[126]  G. Anderson Children Versus Adults: Pharmacokinetic and Adverse‐Effect Differences , 2002, Epilepsia.

[127]  J. Cramer,et al.  Barbiturate-related connective tissue disorders. , 1989, Archives of internal medicine.

[128]  Adrienne M. Rothstein,et al.  Zonisamide and associated oligohidrosis and hyperthermia , 2004, Epilepsy Research.

[129]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[130]  M. Pirmohamed,et al.  TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients , 2001, Neurology.

[131]  M. Béné,et al.  Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. , 1997, Archives of dermatology.

[132]  Norrima Mokhtar,et al.  Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia , 1998, International journal of dermatology.

[133]  M. Oechsner,et al.  Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency , 1998, Journal of neurology, neurosurgery, and psychiatry.

[134]  M. Pirmohamed,et al.  Characterization of drug-specific T cells in lamotrigine hypersensitivity. , 2003, The Journal of allergy and clinical immunology.

[135]  J. Uetrecht,et al.  Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. , 2002, Current drug metabolism.

[136]  W. Santos,et al.  The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: a reactive metabolite in felbamate bioactivation. , 2001, Chemical research in toxicology.

[137]  R. Naclerio,et al.  Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin. , 1983, The Journal of allergy and clinical immunology.

[138]  F. Matsuo,et al.  Anticonvulsant-Induced Cutaneous Reactions , 1999 .

[139]  K. Farrell,et al.  Effects of Age and Polytherapy, Risk Factors of Valproic Acid (VPA) Hepatotoxicity, on the Excretion of Thiol Conjugates of (E)‐2,4‐diene VPA in People with Epilepsy Taking VPA , 2003, Epilepsia.

[140]  J. Uetrecht,et al.  Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. , 1999, The Journal of pharmacology and experimental therapeutics.

[141]  M. Paganini,et al.  Acute changes of blood ammonia may predict short‐term adverse effects of valproic acid , 1984, Neurology.

[142]  W. Pichler Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept , 2002, Current opinion in allergy and clinical immunology.

[143]  M. Pirmohamed,et al.  Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. , 1995, Biochemical pharmacology.

[144]  M. Brodie,et al.  Effectiveness of First Antiepileptic Drug , 2001, Epilepsia.

[145]  J. Messenheimer,et al.  Safety Review of Adult Clinical Trial Experience with Lamotrigine , 1998, Drug safety.

[146]  M. Rieder In vivo and in vitro testing for adverse drug reactions. , 1997, Pediatric clinics of North America.

[147]  R. Geha,et al.  The H1 histamine receptor regulates allergic lung responses. , 2006, The Journal of clinical investigation.

[148]  M. Mockenhaupt,et al.  Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? , 2007, The British journal of dermatology.

[149]  H. Hmouda,et al.  Valproic acid-induced pancreatitis , 2007, Journal of Gastroenterology.

[150]  M. Pirmohamed,et al.  Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster , 2006, Pharmacogenetics and genomics.

[151]  G. Krauss Current Understanding of Delayed Anticonvulsant Hypersensitivity Reactions , 2006, Epilepsy currents.

[152]  C. D. Thompson,et al.  Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. , 1997, Chemical research in toxicology.

[153]  F. Besag,et al.  Successful re-introduction of lamotrigine after initial rash , 2000, Seizure.

[154]  K. Frutig,et al.  T Cells Isolated from Positive Epicutaneous Test Reactions to Amoxicillin and Ceftriaxone are Drug Specific and Cytotoxic , 2000 .

[155]  C. Foster,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[156]  E. Maggi The TH1/TH2 paradigm in allergy. , 1998, Immunotechnology : an international journal of immunological engineering.

[157]  P. Gisondi,et al.  Immunoregulation of Allergic Contact Dermatitis , 2004, The Journal of dermatology.

[158]  P. Loiseau Tolerability of Newer and Older Anticonvulsants , 1996 .

[159]  S. Spielberg,et al.  Familial occurrence of hypersensitivity to phenytoin. , 1991, The American journal of medicine.

[160]  C. Holtzer,et al.  Phenytoin-Induced Thrombocytopenia , 1997, The Annals of pharmacotherapy.

[161]  Katharina Fleischhauer,et al.  Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans , 2006, Immunological reviews.

[162]  M. Pirmohamed,et al.  HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.

[163]  J. Woodfolk Cytokines as a therapeutic target for allergic diseases: a complex picture. , 2006, Current pharmaceutical design.

[164]  U. Stephani,et al.  Severe Hepatotoxicity During Valproate Therapy: An Update and Report of Eight New Fatalities , 1994, Epilepsia.

[165]  R. Pieters,et al.  Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. , 2004, Chemical research in toxicology.

[166]  J. Roujeau,et al.  Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. , 1987, Archives of dermatology.

[167]  Hsin-An Chang,et al.  Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[168]  F. Dreifuss,et al.  Valproic acid hepatic fatalities. III. U.S. experience since 1986 , 1996, Neurology.

[169]  J. Cramer,et al.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. , 1992, The New England journal of medicine.

[170]  M Pirmohamed,et al.  Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. , 1998, Chemical research in toxicology.

[171]  W. Simpson,et al.  Phenytoin-associated reversible red cell aplasia. , 1979, Canadian Medical Association journal.

[172]  I. Choonara,et al.  Surveillance for fatal suspected adverse drug reactions in the UK , 2002, Archives of disease in childhood.

[173]  X. Vidal,et al.  Population-based drug-induced agranulocytosis. , 2005, Archives of internal medicine.

[174]  T. Bohan,et al.  Effect of l-carnitine treatment for valproate-induced hepatotoxicity , 2001, Neurology.

[175]  M. Pirmohamed,et al.  Carbamazepine‐induced acute liver failure as part of the DRESS syndrome , 2005, International journal of clinical practice.

[176]  F. Dreifuss Valproic acid hepatic fatalities≔ Revised table , 1989, Neurology.

[177]  M. Tohyama,et al.  Reactivation of human herpesvirus (HHV) family members other than HHV‐6 in drug‐induced hypersensitivity syndrome , 2006, The British journal of dermatology.

[178]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[179]  Toru Watanabe,et al.  Secondary renal Fanconi syndrome caused by valproate therapy , 2005, Pediatric Nephrology.

[180]  N. Schaul,et al.  Thrombocytopenia in association with adjunctive felbamate use , 1994, Neurology.

[181]  Timothy A. Pedley,et al.  Epilepsy : a comprehensive textbook , 2008 .

[182]  J. Edinger,et al.  Reversible parkinsonism and cognitive impairment with chronic valproate use , 1996, Neurology.

[183]  G. Bennett,et al.  Protein-reactive metabolites of carbamazepine in mouse liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[184]  E. Masliah,et al.  Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. , 2002, Digestive diseases and sciences.

[185]  A. Schulze-Bonhage,et al.  Myoclonus in Epilepsy Patients with Anticonvulsive Add‐On Therapy with Pregabalin , 2001, Epilepsia.

[186]  R. Hehlmann,et al.  Fatal Liver Failure Associated with Valproate Therapy in a Patient with Friedreich's Disease: Review of Valproate Hepatotoxicity in Adults , 1999, Epilepsia.

[187]  A. Li,et al.  Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. , 2002, Chemico-biological interactions.

[188]  F. Dreifuss,et al.  Valproate‐Associated Pancreatitis , 1993, Epilepsia.

[189]  S. Shapiro,et al.  Evaluation of Case Reports of Aplastic Anemia Among Patients Treated with Felbamate , 1997, Epilepsia.

[190]  E. Bertini,et al.  Antioxidant enzymes in blood of patients with Friedreich's ataxia , 2002, Archives of disease in childhood.

[191]  J. Goraya,et al.  Carbamazepine-induced immune thrombocytopenia. , 2003, Neurology India.

[192]  Trevor N Johnson,et al.  The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. , 2003, Toxicology.

[193]  J. Sackellares,et al.  Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. , 1997, Neurology.

[194]  P. Demoly,et al.  Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? , 2006, The British journal of dermatology.

[195]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[196]  A. Ural,et al.  Leucopenia and thrombocytopenia possibly associated with lamotrigine use in a patient. , 2005, Epileptic disorders : international epilepsy journal with videotape.

[197]  S. Spielberg,et al.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. , 1988, The Journal of clinical investigation.

[198]  Joseph T. DiPiro,et al.  Pharmacotherapy: A pathophysiologic approach , 1992 .

[199]  D. Turnbull,et al.  Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[200]  E. Perucca,et al.  Reversible Pseudoatrophy of the Brain and Mental Deterioration Associated with Valproate Treatment , 1998, Epilepsia.

[201]  Hanns Lochmüller,et al.  Drug-induced systemic lupus erythematosus after 8 years of treatment with carbamazepine , 1998, European Journal of Clinical Pharmacology.

[202]  S. Shinnar,et al.  Felbamate: Consensus of current clinical experience , 2006, Epilepsy Research.

[203]  R. Portman,et al.  Pancreatitis in children on chronic dialysis treated with valproic acid , 1990, Pediatric Nephrology.

[204]  E. Perucca,et al.  Progress report on new antiepileptic drugs A summary of the Second Eilat Conference , 1995, Epilepsy Research.

[205]  P. Wen,et al.  Allergic Skin Reactions to Anticonvulsant Medications in Patients Receiving Cranial Radiation Therapy , 1999, Epilepsia.

[206]  F. Sharbrough,et al.  Movement Disorders Associated with the Use of Gabapentin , 1996, Epilepsia.

[207]  R. Benner,et al.  Allergy to Carbamazepine: Parallel In Vivo and In Vitro Detection , 1996, Epilepsia.

[208]  M. Seip APLASTIC ANEMIA DURING ETHOSUXIMIDE MEDICATION , 1983 .

[209]  J. Messenheimer Rash with Lamotrigine: Dosing Guidelines , 2000, Epilepsia.

[210]  W. Pichler,et al.  Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions , 2006, The AAPS Journal.